HALO [NASD]
Halozyme Therapeutics, Inc.
Index- P/E35.34 EPS (ttm)1.49 Insider Own0.80% Shs Outstand136.53M Perf Week2.75%
Market Cap7.15B Forward P/E18.96 EPS next Y2.78 Insider Trans-12.49% Shs Float133.75M Perf Month-3.14%
Income211.20M PEG1.14 EPS next Q0.47 Inst Own100.00% Short Float / Ratio6.48% / 6.68 Perf Quarter11.66%
Sales580.60M P/S12.31 EPS this Y200.60% Inst Trans3.50% Short Interest8.67M Perf Half Y16.39%
Book/sh0.71 P/B74.15 EPS next Y25.49% ROA14.30% Target Price56.22 Perf Year53.13%
Cash/sh1.96 P/C26.92 EPS next 5Y31.00% ROE99.70% 52W Range32.00 - 59.46 Perf YTD-7.69%
Dividend- P/FCF30.09 EPS past 5Y40.20% ROI38.10% 52W High-11.66% Beta1.27
Dividend %- Quick Ratio5.00 Sales past 5Y24.80% Gross Margin79.50% 52W Low64.16% ATR1.62
Employees145 Current Ratio6.00 Sales Q/Q80.50% Oper. Margin42.50% RSI (14)48.23 Volatility2.62% 3.05%
OptionableYes Debt/Eq15.51 EPS Q/Q-70.10% Profit Margin36.40% Rel Volume0.31 Prev Close52.65
ShortableYes LT Debt/Eq15.37 EarningsNov 08 AMC Payout0.00% Avg Volume1.30M Price52.53
Recom2.30 SMA200.62% SMA50-4.36% SMA20011.27% Volume129,934 Change-0.24%
Dec-21-22Resumed Morgan Stanley Overweight $53 → $65
Nov-28-22Initiated Wells Fargo Overweight $65
Sep-09-22Initiated Morgan Stanley Overweight $50
May-23-22Initiated SVB Leerink Outperform $52
Jun-14-21Initiated Evercore ISI Outperform
May-17-21Initiated SVB Leerink Outperform $56
May-11-21Downgrade Piper Sandler Overweight → Neutral $50 → $48
Jan-21-21Reiterated The Benchmark Company Buy $46 → $59
Dec-17-20Initiated Berenberg Buy $50
Sep-14-20Resumed JP Morgan Overweight $28
Show Previous Ratings
Feb-06-23 08:30AM
Feb-02-23 03:02AM
Jan-23-23 06:54AM
Jan-20-23 06:58AM
Jan-12-23 09:47AM
08:30AM Loading…
Jan-11-23 08:30AM
Jan-10-23 05:36PM
05:15PM
Jan-04-23 09:45AM
Jan-03-23 08:30AM
07:29AM
Dec-29-22 05:00AM
Dec-28-22 06:41AM
Dec-08-22 11:30AM
Dec-07-22 06:47AM
04:28AM Loading…
Nov-30-22 04:28AM
Nov-27-22 05:27PM
Nov-25-22 11:48AM
09:45AM
Nov-22-22 11:40AM
Nov-15-22 12:09PM
09:40AM
Nov-11-22 01:48PM
12:08PM
08:25AM
Nov-10-22 05:42AM
Nov-09-22 04:50PM
10:17AM
08:30AM
Nov-08-22 05:35PM
04:01PM Loading…
04:01PM
Nov-07-22 11:06AM
Nov-01-22 10:01AM
Oct-25-22 10:01AM
08:30AM
Oct-03-22 01:06PM
Sep-30-22 10:27AM
Sep-21-22 10:43AM
Sep-08-22 11:30AM
Sep-01-22 08:30AM
Aug-15-22 10:32PM
07:00AM
Aug-10-22 03:13PM
07:48AM
Aug-09-22 06:15PM
04:01PM
Aug-02-22 12:55AM
Jul-26-22 08:30AM
Jul-13-22 09:14AM
Jul-08-22 07:22AM
Jul-06-22 08:08AM
Jul-01-22 01:13PM
Jun-27-22 06:15AM
Jun-21-22 09:13AM
Jun-09-22 11:30AM
Jun-08-22 08:30AM
Jun-07-22 08:30AM
Jun-06-22 06:55AM
May-25-22 09:40AM
May-24-22 08:30AM
May-19-22 12:15PM
09:35AM
May-17-22 10:44AM
May-16-22 09:40AM
May-12-22 09:26AM
08:00AM
May-11-22 09:36AM
May-10-22 05:25PM
04:01PM
May-09-22 09:35AM
May-04-22 08:45AM
May-03-22 02:20PM
Apr-26-22 08:00AM
Apr-22-22 10:22AM
Apr-14-22 01:34PM
10:06AM
10:06AM
06:26AM
Apr-13-22 04:16PM
02:09PM
09:12AM
08:47AM
08:45AM
08:33AM
07:43AM
06:44AM
06:21AM
06:12AM
06:00AM
Apr-06-22 08:24AM
Apr-01-22 08:30AM
Mar-30-22 06:30AM
Mar-25-22 09:47AM
Mar-24-22 11:30AM
10:41AM
08:00AM
Mar-23-22 08:42AM
Mar-22-22 12:22PM
02:15AM
Mar-21-22 08:30AM
Halozyme Therapeutics, Inc. operates as a biopharma technology platform company in the United States, Switzerland, Ireland, Belgium, Japan, and internationally. The company's products are based on the ENHANZE drug delivery technology, a patented recombinant human hyaluronidase enzyme (rHuPH20) that enables the subcutaneous delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids. Its flagship product is Hylenex recombinant, a formulation of rHuPH20 to facilitate subcutaneous fluid administration for achieving hydration to enhance the dispersion and absorption of other injected drugs in subcutaneous urography and to improve resorption of radiopaque agents. The company also develops Perjeta; RITUXAN HYCELA and MabThera SC for the treatment of non-Hodgkin lymphoma and chronic lymphocytic leukemia (CLL); RITUXAN SC for patients with CLL; and HYQVIA for the treatment of immunodeficiency disorders. In addition, it is developing Tecentriq for non-small cell lung cancer; OCREVUS for multiple sclerosis; DARZALEX for the treatment of patients with amyloidosis, smoldering myeloma, and multiple myeloma; nivolumab for the treatment of solid tumors; ARGX-113, a human neonatal Fc receptor; ARGX-117 to treat autoimmune diseases; and BMS-986179, an anti-CD-73 antibody. The company has collaborations with F. Hoffmann-La Roche, Ltd.; Hoffmann-La Roche, Inc.; Baxalta US Inc.; Baxalta GmbH; Pfizer Inc.; Janssen Biotech, Inc.; AbbVie, Inc.; Eli Lilly and Company; Bristol-Myers Squibb Company; Alexion Pharma Holding; ARGENX BVBA; Horizon Therapeutics plc; National Institute of Allergy and Infectious Diseases; Centre for the AIDS Programme of Research in South Africa; and ViiV Healthcare Limited for small and large molecule targets for the treatment and prevention of HIV. Halozyme Therapeutics, Inc. was founded in 1998 and is based in San Diego, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Torley HelenPRESIDENT AND CEOJan 19Option Exercise14.6610,000146,600597,177Jan 19 05:07 PM
Torley HelenPRESIDENT AND CEOJan 19Sale52.4110,000524,140587,177Jan 19 05:07 PM
Torley HelenPRESIDENT AND CEOJan 18Option Exercise14.6610,000146,600597,177Jan 19 05:07 PM
Torley HelenPRESIDENT AND CEOJan 18Sale51.0510,000510,470587,177Jan 19 05:07 PM
Torley HelenPRESIDENT AND CEOJan 17Option Exercise14.6610,000146,600597,177Jan 19 05:07 PM
LaBarre Michael J.SVP, CHIEF TECHNICAL OFFICERJan 17Sale50.4610,000504,590143,137Jan 18 07:07 PM
Torley HelenPRESIDENT AND CEOJan 17Sale50.4510,000504,539587,177Jan 19 05:07 PM
Snyder Mark HowardSVP, GENERAL COUNSELJan 03Option Exercise0.007,61107,611Jan 04 06:00 PM
Torley HelenPRESIDENT AND CEODec 15Option Exercise14.6610,000146,600597,177Dec 15 07:12 PM
Torley HelenPRESIDENT AND CEODec 15Sale57.3710,000573,694587,177Dec 15 07:12 PM
Torley HelenPRESIDENT AND CEODec 14Option Exercise14.6610,000146,600597,177Dec 15 07:12 PM
Torley HelenPRESIDENT AND CEODec 14Sale58.3010,000582,980587,177Dec 15 07:12 PM
Torley HelenPRESIDENT AND CEODec 13Option Exercise14.6610,000146,600597,177Dec 15 07:12 PM
Torley HelenPRESIDENT AND CEODec 13Sale58.6610,000586,627587,177Dec 15 07:12 PM
LaBarre Michael J.SVP, CHIEF TECHNICAL OFFICERDec 13Sale58.6710,000586,675153,137Dec 13 06:09 PM
Posard Matthew L.DirectorDec 06Sale56.1210,000561,180105,189Dec 06 07:07 PM
Posard Matthew L.DirectorDec 05Sale55.7410,000557,370115,189Dec 06 07:07 PM
Posard Matthew L.DirectorDec 02Sale58.8010,000588,000125,189Dec 06 07:07 PM
Torley HelenPRESIDENT AND CEONov 17Option Exercise14.6610,000146,600597,177Nov 17 05:09 PM
Torley HelenPRESIDENT AND CEONov 17Sale52.1510,000521,490587,177Nov 17 05:09 PM
Torley HelenPRESIDENT AND CEONov 16Option Exercise14.6610,000146,600597,177Nov 17 05:09 PM
Torley HelenPRESIDENT AND CEONov 16Sale53.9010,000538,990587,177Nov 17 05:09 PM
Torley HelenPRESIDENT AND CEONov 15Option Exercise14.6610,000146,600597,177Nov 17 05:09 PM
LaBrosse NicoleSVP, CHIEF FINANCIAL OFFICERNov 15Sale53.815,000269,0534,045Nov 16 07:51 PM
LaBarre Michael J.SVP, CHIEF TECHNICAL OFFICERNov 15Sale54.1310,000541,263163,137Nov 16 07:25 PM
Torley HelenPRESIDENT AND CEONov 15Sale54.1110,000541,146587,177Nov 17 05:09 PM
LaBarre Michael J.SVP, Chief Technical OfficerFeb 15Option Exercise0.003,3860174,307Feb 17 06:04 PM
LaBrosse NicoleSVP, Chief Financial OfficerFeb 15Option Exercise0.001,25509,478Feb 17 06:03 PM
Torley HelenPresident and CEOFeb 15Option Exercise0.0013,0920594,069Feb 17 06:02 PM
LaBarre Michael J.SVP, Chief Technical OfficerFeb 14Option Exercise0.005,7710172,916Feb 14 07:29 PM
LaBrosse NicoleSVP, Chief Financial OfficerFeb 14Option Exercise0.001,25608,650Feb 14 07:28 PM
Torley HelenPresident and CEOFeb 14Option Exercise0.0028,7290596,102Feb 14 07:27 PM
LaBarre Michael J.SVP, Chief Technical OfficerFeb 12Option Exercise0.007,8830169,870Feb 14 07:29 PM
LaBrosse NicoleSVP, Chief Financial OfficerFeb 12Option Exercise0.001,38907,900Feb 14 07:28 PM
Torley HelenPresident and CEOFeb 12Option Exercise0.0032,7950584,639Feb 14 07:27 PM
LaBarre Michael J.SVP, Chief Technical OfficerFeb 10Option Exercise0.008,1330164,979Feb 14 07:29 PM
LaBrosse NicoleSVP, Chief Financial OfficerFeb 10Option Exercise0.002,50307,536Feb 14 07:28 PM
Torley HelenPresident and CEOFeb 10Option Exercise0.0031,2820568,442Feb 14 07:27 PM